Skip to main content

BioDuro and Sundia Merge to Form China-US CRDMO Backed by Advent

BioDuro and Sundia, both of them pre-clinical China-US CROs, have partnered to form one of the largest CRDMOs with operations in China and the US . As part of the deal, Advent, a Boston  private equity investor, will lead a majority investment in Sundia. In early 2019, Advent acquired control of BioDuro, also via a majority investment. The new company, which will operate as BioDuro-Sundia, will offer drug discovery, development and manufacturing for both APIs and drug products. Bridgewest Capital was a co-investor in Sundia. Financial terms were not disclosed. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.